Shots:

• The first P-III AReSVi 004 study evaluates the immunogenicity- safety- reactogenicity and persistence of RSV candidate vaccine in 1650 adults ≥ aged 60 years. The study is expected to end in early 2024- with interim results expected to be available in the H1’ 2022
• The second P-III AReSVi 006 study assessing the efficacy of RSV candidate vaccine to help protect older adults against lower-respiratory tract disease and is expected to start in the coming months
• The P- I/II results of vaccine candidate showed promising safety and immunogenicity in both young and older adults and was well-tolerated. The data presented at the ID Week Congress in October 2020

 ­ Ref: GSK | Image: GSK